Therapeutic Strategies in the Second Line Setting of Advanced or Metastatic Pancreatic Adenocarcinoma

Pancreatic cancer is a lethal disease and its prognosis remains dismal. The modest results of existing available treatments inthe second line setting reveal the need of new therapeutic strategies. In this year’s American Society of Clinical Oncology(ASCO) Annual Meeting two remarkable trials and one retrospective analysis were presented regarding this vulnerablegroup of patients. According to the published results, docetaxel plus oxaliplatin (Abstract #4034), selumetinib plus erlotinib(Abstract #4014) and nab-paclitaxel (Abstract #e15057) have shown promising efficacy and manageable toxicity that shouldbe elucidated and confirmed by new prospective, large, randomized trials.


Muhammad Wasif Saif, Kostas N Syrigos, Vasilis Stefanos Ramfidis

Abstract | Full-Text | PDF

Share this  Facebook  Twitter  LinkedIn  Google+
30+ Million Readerbase
Recommended Conferences
Flyer image
Abstracted/Indexed in
  • Index Copernicus
  • Academic Journals Database
  • Genamics JournalSeek
  • Academic Keys
  • China National Knowledge Infrastructure (CNKI)
  • CiteFactor
  • Scimago
  • British Library
  • Electronic Journals Library
  • Directory of Research Journal Indexing (DRJI)
  • WorldCat
  • Emerging Sources Citation Index (ESCI)
  • EBSCO Host
  • MIAR
  • International Committee of Medical Journal Editors (ICMJE)
  • University of Zurich - UZH
  • University Grants Commission
  • SWB Online-Katalog
  • Scholarsteer
  • Geneva Foundation for Medical Education and Research
  • Secret Search Engine Labs